LEADING A NEW PARADIGM IN CARDIOVASCULAR DISEASE MANAGEMENT
Amarin Corporation is focused on a BOLD vision to stop heart disease from being a leading cause of death. Our lead commercial product, VASCEPA® (icosapent ethyl), creates a new paradigm in cardiovascular disease management and is positioned to address cardiovascular risk for millions of patients globally.
The efficacy and safety profile of VASCEPA, as demonstrated in the landmark REDUCE-IT® cardiovascular outcomes study, has been heralded as one of the most significant breakthroughs in preventative cardiovascular care since statin therapy was introduced nearly three decades ago. VASCEPA is supported by over 100 scientific publications and presentations and recommended for use in appropriate at-risk patients by leading medical societies from around the world, including the United States and Europe. The REDUCE-IT results stand in stark contrast to earlier generation drugs, the clinical studies of which failed to show reduction of persistent cardiovascular risk in their studied populations.
Amarin Receives Positive Recommendation from United Kingdom’s (UK) National Institute for Health and Care Excellence (NICE) for Reimbursement of VAZKEPA® (icosapent ethyl)
Jun 10, 2022
UK’s NICE issued its draft Final Appraisal Document (FAD) recommending the use of VAZKEPA® (icosapent ethyl) in England and Wales to reduce the risk of cardiovascular (CV) events in adult statin-treated patients at high CV risk who have elevate...
Amarin Announces Comprehensive Cost Reduction Plan to Address Market Dynamics in U.S. Business
Jun 06, 2022
-- Company Expects to Achieve Approximately $100 Million in Cost Savings Over the Next 12 Months* While Continuing to Invest in European Launches and Global Expansion -- -- Reduces U.S. Commercial Organization by Ninety Percent of Pre-Pandemic...
-- Experienced Executive Brings More Than Twenty Years of Global Financial Leadership to Amarin -- -- Michael W. Kalb to Depart Amarin to Pursue Other Interests -- DUBLIN, Ireland and BRIDGEWATER, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Am...
Erin Enright and Alfonso “Chito” Zulueta Appointed to Board of Directors New Board Members Bring Skills and Experience Aligned with the Company’s Strategy Per Wold-Olsen Named Chairman of the Board David Stack and Joe Zakrzewski to Ret...